About
47.30USD-0.09 -0.19%
Closed • Updated at 12:57 GMT+00:00Market Cap$6.83B
Volume1.33M
Beta0.79
RSI28.69
Vaxcyte, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 6 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Apr 7 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Mar 23 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Mar 18 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Feb 24 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Recent Videos

Vaxcyte (PCVX) Stock Analysis 2026: Zero Revenue, $8B Valuation & 200% Returns
May 01, 2026

Vaccines Update – 3 April 2026: VAX-31 Phase 3, Qdenga India Nod and More
Apr 03, 2026

How to Invest in Vaxcyte Inc (PCVX) Step by Step
Mar 01, 2026

Vaxcyte, Inc. (PCVX) #HealthcareStocks #VaccineStock #VaccineDevelopment #BiotechStocks
Feb 28, 2026
Community Chat
Ask AI
Try asking
Translate